Can-Fite BioPharma: Seikagaku Corporation, the Exclusive Licensee of CF101 in Japan, Is to Commence Phase I Clinical Trial in Japan With CF101 for the Treatment of Rheumatoid Arthritis
8/18/2008 8:46:37 AM
More...
|
Can-Fite BioPharma Progresses Through Clinical Trials: Completed Enrollment Of Half The Patients Required For Phase IIb RA Trial And Is Scheduled To Receive Next Payment Fom The Japanese Seikagaku Corporation
10/23/2006 10:59:23 AM
More...
|
Seikagaku Corporation Obtains Sales Distribution Approval For MukoUp
10/20/2006 12:44:07 PM
More...
|
Can-Fite BioPharma Out Licenses Rights For Its Drug, CF101, In Japan To The Seikagaku Corporation And Expects To Receive US$ 19.5 Million From Licensing Fees And Milestone Payments And Collect Substantial Royalties
9/25/2006 10:26:52 AM
More...
|
Seikagaku Corporation To Begin Clinical Trials Of Injectable Hyaluronic Acid Gel For Knee Osteoarthritis Treatment In US
7/20/2006 7:34:29 PM
More...
|
Discovery Partners International Inc. (DPII) Announces Receipt Of Success Milestone Payment In Its Lead Finding Collaboration With Seikagaku Corporation
11/9/2005 10:46:51 AM
More...
|